

# Primary Biliary Cirrhosis - Pipeline Review, H2 2018

<https://marketpublishers.com/r/P13C44A28EFEN.html>

Date: July 2018

Pages: 125

Price: US\$ 2,000.00 (Single User License)

ID: P13C44A28EFEN

## Abstracts

Primary Biliary Cirrhosis - Pipeline Review, H2 2018

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2018, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea.

Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase

III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 12, 3, 1, 1 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Primary Biliary Cirrhosis - Overview
- Primary Biliary Cirrhosis - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Primary Biliary Cirrhosis - Therapeutics Assessment
  - Assessment by Target
  - Assessment by Mechanism of Action
  - Assessment by Route of Administration
  - Assessment by Molecule Type
- Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
  - Albireo Pharma Inc
  - Arena Pharmaceuticals Inc
  - Biocad
  - Cadila Healthcare Ltd
  - CymaBay Therapeutics Inc
  - Dr. Falk Pharma GmbH
  - Eisai Co Ltd
  - Enanta Pharmaceuticals Inc
  - Genfit SA
  - GenKyoTex SA
  - Gilead Sciences Inc
  - GlaxoSmithKline Plc
  - Intercept Pharmaceuticals Inc
  - Kowa Co Ltd
  - NGM Biopharmaceuticals Inc
  - Novartis AG
  - Tiziana Life Sciences Plc
  - Virobay Inc
- Primary Biliary Cirrhosis - Drug Profiles
  - A-4250 - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - BCD-085 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
E-6011 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
EDP-305 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
elafibranor - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
etrasimod arginine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
FFP-104 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
foralumab - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
GKT-831 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
GS-9674 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
GSK-2330672 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pemafibrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saroglitazar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar lysine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tropifexor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ursodiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZG-5216 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Biliary Cirrhosis - Dormant Projects

Primary Biliary Cirrhosis - Product Development Milestones

Featured News & Press Releases

Jun 05, 2018: Court Appoints Faruqi & Faruqi As Lead Counsel For Class Action Against Intercept Pharmaceuticals

May 07, 2018: Genkyotex Announces Positive Outcome from Independent SMB's First Pre-Planned Review of GKT831's Phase 2 Trial in Primary Biliary Cholangitis

Mar 28, 2018: Enanta Pharmaceuticals Announces Poster Presentations on EDP-305 at ICL 2018

Mar 23, 2018: Intercept Announces Multiple New Ocaliva (obeticholic acid) Data Presentations at the International Liver Congress 2018

Nov 01, 2017: Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis

Apr 19, 2017: Intercept Announces New Ocaliva (obeticholic acid) and INT-767 Data to be Presented at EASL 2017

Apr 05, 2017: Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2017

Feb 23, 2017: Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis

Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC

Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC

May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC

May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016

Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Primary Biliary Cirrhosis, H2 2018  
Number of Products under Development by Companies, H2 2018  
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Number of Products by Stage and Target, H2 2018  
Number of Products by Stage and Mechanism of Action, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Biocad, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Cadila Healthcare Ltd, H2 2018  
Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Genfit SA, H2 2018  
Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Kowa Co Ltd, H2 2018  
Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Novartis AG, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Tiziana Life Sciences Plc, H2 2018  
Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H2 2018  
Primary Biliary Cirrhosis - Dormant Projects, H2 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Primary Biliary Cirrhosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Albireo Pharma Inc

Arena Pharmaceuticals Inc

Biocad

Cadila Healthcare Ltd

CymaBay Therapeutics Inc

Dr. Falk Pharma GmbH

Eisai Co Ltd

Enanta Pharmaceuticals Inc

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

Intercept Pharmaceuticals Inc

Kowa Co Ltd

NGM Biopharmaceuticals Inc

Novartis AG

Tiziana Life Sciences Plc

Virobay Inc

## I would like to order

Product name: Primary Biliary Cirrhosis - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/P13C44A28EFEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P13C44A28EFEN.html>